Evotec AG has achieved a key preclinical milestone in the ongoing alliance with Padlock Therapeutics, Inc. for the development of inhibitors of protein-arginine deiminases (PADs) for autoimmune diseases such as rheumatoid arthritis (RA) and lupus. The milestone triggers an undisclosed milestone payment to Evotec. The collaboration, now in its third year, could potentially extend through March 2017. Evotec provides research activities for Padlock including in vitro biology, high-throughput sc...